2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Álvaro Juárez Soto, MD, discusses the rationale for examining apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as seen in the phase 3 TITAN study.
Álvaro Juárez Soto, MD, chief of Urology Service at Hospital Universitario de Jerez, Cádiz, Spain, discusses the rationale for examining apalutamide (Erleada) plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer (mCSPC), as seen in the phase 3 TITAN study (NCT02489318).
Investigators behind the trial set out to demonstrate the safety and efficacy of apalutamide in a broad population of patients who had been diagnosed with mCSPC, according to Juárez Soto. Prior to the study, only high-risk patients with a high tumor volume benefitted from abiraterone acetate (Zytiga). The regimen is a new strategy that provides benefit to a broad population of patients, Juárez Soto concludes.